Success Metrics

Clinical Success Rate
25.0%

Based on 1 completed trials

Completion Rate
25%(1/4)
Active Trials
0(0%)
Results Posted
400%(4 trials)
Terminated
3(75%)

Phase Distribution

Ph phase_3
4
100%

Phase Distribution

0

Early Stage

0

Mid Stage

4

Late Stage

Phase Distribution4 total trials
Phase 3Large-scale testing
4(100.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

25.0%

1 of 4 finished

Non-Completion Rate

75.0%

3 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Completed(1)
Terminated(3)

Detailed Status

Terminated3
Completed1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
25.0%
Most Advanced
Phase 3

Trials by Phase

Phase 34 (100.0%)

Trials by Status

completed125%
terminated375%

Recent Activity

0 active trials
Showing 4 of 4
terminatedphase_3

Study to Evaluate the Long-term Safety and Tolerability of USL261 in Patients With Seizure Clusters

NCT01529034
completedphase_3

Study to Evaluate the Safety and Efficacy of USL261 in Patients With Increased Bouts of Seizure Activity in the EMU

NCT01999777
terminatedphase_3

Study to Evaluate the Safety and Efficacy of USL261 (Intranasal Midazolam) in Patients With Seizure Clusters

NCT01390220
terminatedphase_3

A Long-term Safety and Tolerability Study of USL261 in Patients With Seizure Clusters

NCT02161185

Clinical Trials (4)

Showing 4 of 4 trials
NCT01529034Phase 3

Study to Evaluate the Long-term Safety and Tolerability of USL261 in Patients With Seizure Clusters

Terminated
NCT01999777Phase 3

Study to Evaluate the Safety and Efficacy of USL261 in Patients With Increased Bouts of Seizure Activity in the EMU

Completed
NCT01390220Phase 3

Study to Evaluate the Safety and Efficacy of USL261 (Intranasal Midazolam) in Patients With Seizure Clusters

Terminated
NCT02161185Phase 3

A Long-term Safety and Tolerability Study of USL261 in Patients With Seizure Clusters

Terminated

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4